February 4, 2012
Pharmacy news, jobs, continuing education, community and more.
The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic). Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are [...]
NEW YORK - Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. Following a review by the independent Data Monitoring Committee (DMC), the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm [...]
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant [...]
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for
Novartis Consumer Health Inc. (NCH) informed customers, that it is voluntarily recalling all lots of select bottle packaging configurations from retailers of Excedrin® and NoDoz® products with expiry
This past June in a tiny pharmacy in the sleepy suburban town of Medford, New York, a deranged gunman high on prescription drugs executed four innocent victims in cold blood. “In all of my law … [Read More...]
© Rx Times, LLC 2011. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.